share_log

Morgan Stanley Maintains Overweight on Silence Therapeutics, Lowers Price Target to $45

Benzinga ·  Mar 5 14:08

Morgan Stanley analyst Michael Ulz maintains Silence Therapeutics (NASDAQ:SLN) with a Overweight and lowers the price target from $49 to $45.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 346

Recommended

Write a comment